CERo Therapeutics Unveils Promising Preclinical Results for Ovarian Cancer CERo Therapeutics has presented data showing its lead compound, CER-1236, effectively targets ovarian cancer cells with no observed toxicity in animal models. The findings, unveiled at the SITC Spring Scientific Meeting, highlight the compound’s potential for broader applications, including lung cancer. Clinical trials are anticipated to begin later in 2025.12